Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood.
D000328:Adult; D017209:Apoptosis / Q000235:genetics / Q000276:immunology; D001254:Astrocytoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D001932:Brain Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000235:genetics / Q000276:immunology*; D002528:Cerebellar Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D002648:Child; D003601:Cytotoxicity Tests, Immunologic; D053222:Fas Ligand Protein; D005312:Fetal Blood / Q000166:cytology*; D015870:Gene Expression; D006801:Humans; D016219:Immunotherapy, Adoptive; D007231:Infant, Newborn; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008527:Medulloblastoma / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008562:Membrane Glycoproteins / Q000235:genetics; D054353:Perforin; D052899:Pore Forming Cytotoxic Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured / Q000276:immunology* / Q000473:pathology
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D052899:Pore Forming Cytotoxic Proteins; D054353:Perforin